Meeting Report
2020–2021 Drug Updates in Solid Tumors
Christine Cambareri, PharmD, BCPS, BCOP, CSP
From University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2022;13(3):275–281 |
https://doi.org/10.6004/jadpro.2022.13.3.19 |
© 2022 Harborside™
ABSTRACT
During JADPRO Live Virtual 2021, Christine Cambareri, PharmD, BCPS, BCOP, CSP, briefed advanced practitioners on drugs and biologics that were approved for the treatment of solid tumors from late 2020 to late 2021, including their adverse event profiles. The trend of more oral dosage forms and the significant number of checkpoint inhibitors approved points towards changing treatment paradigms in the field.
For access to the full length article, please
sign in.
